Gene Patent Stoush Heads to US Court
By Karen Barlow,
ABC News [Australia]
| 12. 08. 2011
The fight over human genes and whether they can be patented for medical research has gone to the US Supreme Court.
The American Civil Liberties Union and the Public Patent Foundation filed their appeal on Thursday, arguing genes are products of nature and cannot be sequestered by private companies.
The case concerns Myriad Genetics, a biotech company that holds patents on two genes that can help reveal susceptibility to breast and ovarian cancer.
There is concern their monopoly position stymies research and restricts patient access to tests and treatment, but the biotech sector and patent lawyers say there are safeguards.
[Audio: Action filed to invalidate gene patents (PM)]
ANU visiting fellow and intellectual property law consultant Luigi Palombi says if a company has a patent on a gene, it can control everything that happens with that gene.
"You can control its use in research, you can control its use in the development of a medicine, you can control its use in the use of a diagnostic, etc.," he said.
"And yet all you've done is discovered a link between a...
Related Articles
By Ali Breland, The Atlantic | 08.20.2024
“Joining us now is Steve Sailer, who I find to be incredibly interesting, and one of the most talented noticers,” Charlie Kirk said on his internet show in October. Kirk, the 30-year-old founder of Turning Point USA, a right-wing...
By Megan Agnew, The Times | 09.15.2024
Faith Hartley always wanted two girls — a blonde and a redhead. “I thought, I’ll have one that looks like me,” says Hartley, 35, smoothing her golden hair in the Los Angeles valley home she shares with her husband, Neil...
By Emily R. Klancher Merchant, Los Angeles Review of Books | 08.22.2024
IN THE Operation Varsity Blues scandal of 2019, 50 wealthy parents were charged with trying to get their children into elite universities through fraudulent means. The story dramatically demonstrated the lengths to which some parents will go to ensure their...
By Julia Brown, The Conversation | 08.16.2024
With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and...